Amputations for extremity soft tissue sarcoma in an era of limb salvage treatment: Local control and survival

Amputations for extremity soft tissue sarcoma in an era of limb salvage treatment: Local control... AbbreviationsDSSdisease‐specific survivalEBRTexternal beam radiotherapyESTSextremity soft tissue sarcomaHILPhyperthermic isolated limb perfusionIRBinstitutional review boardIQRinterquartile rangeLRFSlocal recurrence free survivalLSTlimb salvage treatmentMPNSTmalignant peripheral nerve sheath tumorOSoverall survivalSTSsoft tissue sarcomasUMCGUniversity Medical Center GroningenINTRODUCTIONSoft tissue sarcomas (STS) are rare, malignant tumors with an incidence of 12 310 new cases in the United States and 729 in the Netherlands in 2016, resulting in 4990/300 STS related deaths in the United States and in the Netherlands in 2016. STS form a heterogeneous group of tumors including more than 50 different histologic subtypes. The most common subtypes are pleomorphic undifferentiated sarcoma (including malignant fibrous histiocytoma), liposarcoma, leiomyosarcoma, synovial sarcoma, and malignant peripheral nerve sheath tumor, which account for a total of 76% of all STS. STS can occur at any anatomic location but most often arise in the limbs (60‐70%). Despite complete resection, with or without (neo)adjuvant treatment, STS are known for their potential to recur locally and/or to cause distant metastases, mainly to the lungs. The available data considering the improvement of survival following (neo)adjuvant systemic chemotherapy are inconsistent and under on‐going investigation.Amputation does not increase the survival rate of patients with extremity soft tissue sarcoma (ESTS) when compared with limb salvage surgery combined with (postoperative) radiotherapy. So, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Surgical Oncology Wiley

Amputations for extremity soft tissue sarcoma in an era of limb salvage treatment: Local control and survival

Loading next page...
 
/lp/wiley/amputations-for-extremity-soft-tissue-sarcoma-in-an-era-of-limb-20eGCAf0rN
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
© 2018 Wiley Periodicals, Inc.
ISSN
0022-4790
eISSN
1096-9098
D.O.I.
10.1002/jso.24881
Publisher site
See Article on Publisher Site

Abstract

AbbreviationsDSSdisease‐specific survivalEBRTexternal beam radiotherapyESTSextremity soft tissue sarcomaHILPhyperthermic isolated limb perfusionIRBinstitutional review boardIQRinterquartile rangeLRFSlocal recurrence free survivalLSTlimb salvage treatmentMPNSTmalignant peripheral nerve sheath tumorOSoverall survivalSTSsoft tissue sarcomasUMCGUniversity Medical Center GroningenINTRODUCTIONSoft tissue sarcomas (STS) are rare, malignant tumors with an incidence of 12 310 new cases in the United States and 729 in the Netherlands in 2016, resulting in 4990/300 STS related deaths in the United States and in the Netherlands in 2016. STS form a heterogeneous group of tumors including more than 50 different histologic subtypes. The most common subtypes are pleomorphic undifferentiated sarcoma (including malignant fibrous histiocytoma), liposarcoma, leiomyosarcoma, synovial sarcoma, and malignant peripheral nerve sheath tumor, which account for a total of 76% of all STS. STS can occur at any anatomic location but most often arise in the limbs (60‐70%). Despite complete resection, with or without (neo)adjuvant treatment, STS are known for their potential to recur locally and/or to cause distant metastases, mainly to the lungs. The available data considering the improvement of survival following (neo)adjuvant systemic chemotherapy are inconsistent and under on‐going investigation.Amputation does not increase the survival rate of patients with extremity soft tissue sarcoma (ESTS) when compared with limb salvage surgery combined with (postoperative) radiotherapy. So,

Journal

Journal of Surgical OncologyWiley

Published: Jan 1, 2018

Keywords: ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off